Technetium (^99mTc) nofetumomab merpentan

Mouse monoclonal antibody

Pharmaceutical compound

Technetium (^99mTc) nofetumomab merpentan
Monoclonal antibody

Type	Fab fragment
Source	Mouse
Clinical data
Trade names	Verluma
ATC code	none
Pharmacokinetic data
Elimination half-life	10.5 hours
Excretion	renal (64%)
Identifiers
CAS Number	165942-79-0 ^☒N
ChemSpider	none
UNII	9UFH75HT7S
^☒NcheckY (what is this?) (verify)

Technetium (^99mTc) nofetumomab merpentan (trade name Verluma) is a mouse monoclonal antibody derivative used in the diagnosis of lung cancer,^[1] gastrointestinal, breast, ovary, pancreas, kidney, cervix, and bladder carcinoma.^[2] The antibody part, nofetumomab, is attached to the chelator merpentan, which links it to the radioisotope technetium-99m (^99mTc).^[3]

Nofetumomab

[edit ]

Nofetumomab is an antibody fragment that recognises the pancarcinoma glycoprotein antigen EpCAM.^[4] and/or CD20/MS4A1 ^[5]

It is the Fab part of murine MAb NR-LU-10.^[6]

Merpentan

[edit ]

The chelator part : merpentan is a phenthioate ligand, 2,3,5,6-tetrafluorophenyl-4,5-bis-5-[1-ethoxyethyl]-thioacetoamidopentanoate.^[6]

Phenthioate

[edit ]

Phenthioate is an insecticide (Cidial) = O,o-dimethyl-S-(carbethoxy-phenylmethyl)dithiophosphate^[7]

References

[edit ]

^ Straka MR, Joyce JM, Myers DT (January 2000). "Tc-99m nofetumomab merpentan complements an equivocal bone scan for detecting skeletal metastatic disease from lung cancer". Clinical Nuclear Medicine. 25 (1): 54–5. doi:10.1097/00003072-200001000-00013. PMID 10634533.
^ Breitz HB, Tyler A, Bjorn MJ, Lesley T, Weiden PL (September 1997). "Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy". Clinical Nuclear Medicine. 22 (9): 615–20. doi:10.1097/00003072-199709000-00007. PMID 9298295.
^ "International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). Geneva: World Health Organization. 2002. Archived from the original (PDF) on July 3, 2011.
^ Tsurushita N, Vasquez M (January 2004). "Humanization of monoclonal antibodies". In Reth M, Radbruch A, Alt F, Honjo T, Neuberger M (eds.). Molecular Biology of B Cells. Academic Press. pp. 533–545. ISBN 978-0-08-047950-7.
^ "Anti-MS4A1 Therapeutic Antibody (Technetium (99MTC) Nofetumomab Merpentan)". Creative BioLabs.
^ ^a ^b Mudd E (27 February 2015). "Monoclonal Antibody Radionuclide Test Kits". Pharmacological Sciences.
^ US 3934010, Drabek J, Varsanyi D, "Insecticidal composition and method utilizing phosphoric acid phenylsulphonamide esters", issued 20 January 1976, assigned to Ciba Geigy Corporation

v
t
e

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab ^§ Amivantamab Ascrinvacumab ^§ Atezolizumab (+hyaluronidase) Balstilimab ^† Botensilimab Cixutumumab ^§ Conatumumab ^§ Cosibelimab Daratumumab Drozitumab ^§ Duligotumab ^§ Dusigitumab ^§ Enfortumab vedotin Enoticumab ^§ Figitumumab ^§ Flanvotumab ^§ Ganitumab ^† Glembatumumab vedotin ^† Intetumumab ^§ Ipilimumab Iratumumab ^§ Istiratumab Icrucumab ^§ Lexatumumab ^§ Lucatumumab ^§ Mapatumumab ^§ Narnatumab ^§ Necitumumab Nesvacumab ^§ Nivolumab ^# (+hyaluronidase, +relatlimab) Ofatumumab Olaratumab ^† Panitumumab Patritumab ^§ Pembrolizumab ^# Pritumumab ^§ Radretumab ^§ Ramucirumab Rilotumumab ^† Robatumumab ^§ Seribantumab ^§ Sugemalimab Tarextumab ^§ Tisotumab vedotin Teprotumumab ^† Tovetumab ^§ Vantictumab ^§ Votumumab ^§ Zalutumumab ^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab ^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab ^§ Bavituximab ^§ Brentuximab vedotin Carotuximab ^† Cetuximab Derlotuximab biotin ^§ Dinutuximab Ecromeximab ^§ Ensituximab ^§ Futuximab ^§ Girentuximab ^† Indatuximab ravtansine ^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab ^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab ^§ Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine ^§ Brontictuzumab ^§ Cantuzumab mertansine ^§ Cantuzumab ravtansine ^§ Cirmtuzumab Citatuzumab bogatox ^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab ^§ Demcizumab ^§ Dalotuzumab ^§ Datopotamab deruxtecan Denintuzumab mafodotin ^§ Elotuzumab Emactuzumab Emibetuzumab ^§ Enoblituzumab ^§ Epcoritamab Etaracizumab ^§ Farletuzumab ^§ Ficlatuzumab ^§ Flotetuzumab ^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab ^§ Inotuzumab ozogamicin Labetuzumab ^§ Lifastuzumab vedotin ^§ Lintuzumab ^§ Lorvotuzumab mertansine ^§ Lumretuzumab ^§ Matuzumab ^§ Milatuzumab ^§ Naxitamab Nimotuzumab ^† Obinutuzumab Ocaratuzumab ^§ Odronextamab Otlertuzumab ^§ Onartuzumab ^§ Oportuzumab monatox ^† Parsatuzumab ^§ Pertuzumab Pinatuzumab vedotin ^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine ^† Sacituzumab govitecan Sibrotuzumab ^§ Simtuzumab ^§ Sofituzumab vedotin ^§ Tacatuzumab tetraxetan ^§ Tigatuzumab ^§ Trastuzumab ^# (+deruxtecan / +emtansine) Tucotuzumab celmoleukin ^§ Vandortuzumab vedotin ^§ Vanucizumab ^§ Veltuzumab ^§ Vorsetuzumab mafodotin ^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab ^§
Chimeric + humanized	Depatuxizumab mafodotin ^† Duvortuxizumab Ontuxizumab ^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

v
t
e

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

v
t
e

Retrieved from "https://en.wikipedia.org/w/index.php?title=Technetium_(99mTc)_nofetumomab_merpentan&oldid=1084076675"